In vivo treatment of rats with monoclonal antibodies against gamma interferon: effects on experimental allergic neuritis

Acta Neurologica Scandinavica
K StrigårdT Olsson

Abstract

To elucidate the role of gamma interferon in experimental allergic neuritis (EAN) a mouse monoclonal antibody (DB-1) directed against rat gamma interferon was used to treat rats during different phases of the development of experimental allergic neuritis (EAN). The effects of this treatment were followed by clinical evaluation, and in some instances by immunohistochemical analysis of lymphoid organs and affected nerves for presence of MHC class II antigens and various T cell subsets. DB-1 treatment given after onset of clinical symptoms (Day 15 after immuniozation with myelin) shortened disease duration, compared with non-treated EAN controls. Affected nerves of DB-1 treated animals showed reduced expression of MHC class II antigens and lower numbers of T lymphocytes within the affected nerves. In contrast, when DB-1 treatment was given on the day of immunization (Day 0), the disease duration increased, and when given before onset of the disease (Day 9) the clinical course was not significantly affected. The results support an important role for gamma interferon in the pathogenesis of EAN.

References

Jun 1, 1979·European Journal of Immunology·W R McMaster, A F Williams
Jun 1, 1986·The Journal of General Virology·P H van der MeideH Schellekens
Nov 1, 1986·The British Journal of Dermatology·A ScheyniusP H van der Meide
Dec 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·A M DuijvestijnE C Butcher
Sep 1, 1987·The Journal of Experimental Medicine·C O JacobH O McDevitt
Oct 1, 1988·Arthritis and Rheumatism·N J MauritzL Klareskog
Jan 1, 1983·Immunological Reviews·D W MasonM L Thomas
Oct 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·L A MatisR H Schwartz
Aug 1, 1980·European Journal of Immunology·R J BrideauA F Williams
Dec 1, 1980·The Journal of Experimental Medicine·M G ScherE R Unanue
Jul 1, 1956·Journal of Neuropathology and Experimental Neurology·B H WAKSMAN, R D ADAMS
Jan 1, 1962·The Journal of Pathology and Bacteriology·K E ASTROM, B H WAKSMAN

❮ Previous
Next ❯

Citations

Jun 25, 1998·Journal of Biomedical Materials Research·I M KhouwM J van Luyn
Jun 1, 1991·Journal of the Neurological Sciences·W Brück, R L Friede
Jul 1, 1993·Journal of the Neurological Sciences·T OlssonH Link
Jun 1, 1996·Cytokine & Growth Factor Reviews·A Billiau
Sep 1, 1994·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·T Olsson
Oct 1, 1992·Journal of Neuroimmunology·H P HartungK V Toyka
Nov 1, 1989·Journal of Neuroscience Research·A LjungdahlB Höjeberg
May 1, 1997·Clinical Immunology and Immunopathology·X F BaiH Link
Feb 1, 1994·European Journal of Immunology·T OlssonK Kristensson
Feb 1, 1995·Muscle & Nerve·H P HartungK V Toyka
Aug 24, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Wesley C ChanRae S M Yeung

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.